OCL 500 Treatment of Women With Symptomatic Uterine Fibroids
Not Applicable
Completed
- Conditions
- Uterine FibroidLeiomyomaMyoma
- Interventions
- Device: Occlusin 500 Microspheres
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2019-09-12
- Lead Sponsor
- IMBiotechnologies Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT03427671
- Locations
- 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
Safety and Efficacy of OCL 503 in Prostate Artery Embolization
Not Applicable
Completed
- Conditions
- Benign Prostatic HyperplasiaBenign Prostatic Hypertrophy
- Interventions
- Device: Prostate artery embolization.
- First Posted Date
- 2015-07-28
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- IMBiotechnologies Ltd.
- Target Recruit Count
- 10
- Registration Number
- NCT02509975
- Locations
- 🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
Safety and Effectiveness of OCL 503 in the Treatment of Women With Leiomyomata
Not Applicable
Completed
- Conditions
- Leiomyomata
- Interventions
- Device: OCL 503 (uterine artery embolization)
- First Posted Date
- 2015-04-07
- Last Posted Date
- 2018-12-05
- Lead Sponsor
- IMBiotechnologies Ltd.
- Target Recruit Count
- 3
- Registration Number
- NCT02410018
- Locations
- 🇺🇸
Albany Medical Center, Albany, New York, United States
© Copyright 2025. All Rights Reserved by MedPath